SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    L.C. Vázquez-Niño, M.I. Rojas-Esquivel, L. Martínez-Huitron, R. Bernal-García, N.E. Valdez-Inzunza, J.J. García-Vázquez, Bloqueo androgénico intermitente y su asociación con la disminución de resistencia a la castración en pacientes con cáncer de próstata, Revista Mexicana de Urología, 2014, 74, 3, 165

    CrossRef

  2. 2
    J. Morote, J. Ropero, J. Planas, A. Celma, J. Placer, R. Ferrer, I. de Torres, Metabolic syndrome in patients with prostate cancer undergoing androgen suppression, Actas Urológicas Españolas (English Edition), 2014, 38, 5, 285

    CrossRef

  3. 3
    Francesco Ricci, Giulia Buzzatti, Alessandra Rubagotti, Francesco Boccardo, Safety of antiandrogen therapy for treating prostate cancer, Expert Opinion on Drug Safety, 2014, 13, 11, 1483

    CrossRef

  4. 4
    J. Morote, J. Ropero, J. Planas, A. Celma, J. Placer, R. Ferrer, I. de Torres, Síndrome metabólico en pacientes con cáncer de próstata sometidos a supresión androgénica, Actas Urológicas Españolas, 2014, 38, 5, 285

    CrossRef

  5. 5
    Philip J. Saylor, Matthew R. Smith, Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, 2013, 189, 1, S34

    CrossRef

  6. 6
    Rana R. McKay, Mary-Ellen Taplin, Toni K. Choueiri, Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer, Hematology/Oncology Clinics of North America, 2013, 27, 6, 1261

    CrossRef

  7. You have free access to this content7
    Jenny P. Nobes, Stephen E.M. Langley, Tanya Klopper, David Russell-Jones, Robert W. Laing, A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy, BJU International, 2012, 109, 10
  8. 8
    Rhoda J Jamadar, Mary J Winters, Pauline M Maki, Cognitive changes associated with ADT: a review of the literature, Asian Journal of Andrology, 2012, 14, 2, 232

    CrossRef

  9. 9
    C Lee, Andrea Kilgour, YK Lau, Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy, BMC Cancer, 2012, 12, 1, 324

    CrossRef

  10. 10
    Carolyn A Allan, Veronica R Collins, Mark Frydenberg, Robert I McLachlan, Kati L Matthiesson, Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy, International Journal of Urological Nursing, 2012, 6, 1
  11. 11
    Andrew Collier, Sujoy Ghosh, Brian McGlynn, Graham Hollins, Prostate Cancer, Androgen Deprivation Therapy, Obesity, the Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease, American Journal of Clinical Oncology, 2012, 35, 5, 504

    CrossRef

  12. 12
    Noboru Hara, Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update, Experimental Diabetes Research, 2012, 2012, 1

    CrossRef

  13. 13
    R B Egerdie, F Saad, M R Smith, T L J Tammela, J Heracek, P Sieber, C Ke, B Leder, R Dansey, C Goessl, Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, Prostate Cancer and Prostatic Diseases, 2012, 15, 3, 308

    CrossRef

  14. 14
    Jacques Planas Morin, Juan Morote Robles, Skeletal complications of ADT: disease burden and treatment options, Asian Journal of Andrology, 2012, 14, 5, 670

    CrossRef

  15. 15
    Joan M. Neuner, William A. See, Liliana E. Pezzin, Sergey Tarima, Ann B. Nattinger, The Association of Robotic Surgical Technology and Hospital Prostatectomy volumes, Cancer, 2012, 118, 2
  16. 16
    Yu-hsiang Lin, Chien-lun Chen, Chen-pang Hou, Phei-lang Chang, Ke-hung Tsui, A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma, Acta Pharmacologica Sinica, 2011, 32, 4, 537

    CrossRef

  17. 17
    Lauren M. Walker, John W. Robinson, A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer, Psycho-Oncology, 2011, 20, 8
  18. 18
    Juan-Jie Bo, Chao Zhang, Lian-Hua Zhang, Ping Liu, Jian-Jun Sha, Jian-Wei Lv, Dong-Ming Liu, Yi-Ran Huang, Zheng Li, Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks, Asian Journal of Andrology, 2011, 13, 6, 833

    CrossRef

  19. 19
    J. Morote, J. Planas, Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation, Actas Urológicas Españolas (English Edition), 2011, 35, 4, 232

    CrossRef

  20. 20
    J. Morote, J. Planas, Pérdida de masa ósea en pacientes con cáncer de próstata sometidos a deprivación androgénica, Actas Urológicas Españolas, 2011, 35, 4, 232

    CrossRef

  21. 21
    Julian Kim, Moninder Vaid, Scott Tyldesley, Ryan Woods, Tom Pickles, Population-Based Study of Cardiovascular Mortality Among Patients With Prostate Cancer Treated With Radical External Beam Radiation Therapy With and Without Adjuvant Androgen Deprivation Therapy at the British Columbia Cancer Agency, International Journal of Radiation Oncology*Biology*Physics, 2011, 80, 3, 742

    CrossRef

  22. 22
    Scott M. Gilbert, Yong-fang Kuo, Vahakn B. Shahinian, Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States, Urologic Oncology: Seminars and Original Investigations, 2011, 29, 6, 647

    CrossRef

  23. 23
    Jason A. Efstathiou, William U. Shipley, Anthony L. Zietman, Matthew R. Smith, Hormonal therapies: ADT for prostate cancer: true love or heartbreak?, Nature Reviews Clinical Oncology, 2010, 7, 3, 130

    CrossRef

  24. 24
    Jason E Faris, Matthew R Smith, Metabolic sequelae associated with androgen deprivation therapy for prostate cancer, Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 3, 240

    CrossRef

  25. 25
    Arthur I. Sagalowsky, Re: Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology, European Urology, 2010, 58, 4, 630

    CrossRef

  26. 26
    Pamela Taxel, Robert Dowsett, Lee Richter, Pamela Fall, Alison Klepinger, Peter Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer, BJU International, 2010, 106, 10
  27. 27
    Hendrik Isbarn, Laurent Boccon-Gibod, Peter R. Carroll, Francesco Montorsi, Claude Schulman, Matthew R. Smith, Cora N. Sternberg, Urs E. Studer, Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks, European Urology, 2009, 55, 1, 62

    CrossRef

  28. 28
    Philip J. Saylor, Matthew R. Smith, Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, 2009, 181, 5, 1998

    CrossRef

  29. 29
    J.P. Nobes, S.E.M. Langley, R.W. Laing, Metabolic Syndrome and Prostate Cancer: A Review, Clinical Oncology, 2009, 21, 3, 183

    CrossRef

  30. 30
    Matthew R. Smith, Gordon A. Brown, Fred Saad, New opportunities in the management of prostate cancer–related bone complications, Urologic Oncology: Seminars and Original Investigations, 2009, 27, 6, S1

    CrossRef

  31. 31
    Philip J. Saylor, Nancy L. Keating, Matthew R. Smith, Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy, Journal of General Internal Medicine, 2009, 24, S2, 389

    CrossRef

  32. 32
    Richard J. Wassersug, John L. Oliffe, The Social Context for Psychological Distress from Iatrogenic Gynecomastia with Suggestions for Its Management, The Journal of Sexual Medicine, 2009, 6, 4
  33. 33
    Anthony Zietman, ACTIVE SURVEILLANCE: A SAFE, LOW-COST PROGNOSTIC TEST FOR PROSTATE CANCER, BJU International, 2008, 101, 9
  34. 34
    Matthew R. Smith, Hang Lee, Mary Anne Fallon, David M. Nathan, Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer, Urology, 2008, 71, 2, 318

    CrossRef

  35. 35
    Matthew R. Smith, Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors, Current Urology Reports, 2008, 9, 3, 197

    CrossRef

  36. 36
    Matthew R. Smith, Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors, Current Prostate Reports, 2008, 6, 4, 149

    CrossRef

  37. 37
    Jason A. Efstathiou, Rafi Y. Skowronski, John J. Coen, Joseph A. Grocela, Ariel E. Hirsch, Anthony L. Zietman, Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, 2008, 71, 5, 1302

    CrossRef

  38. 38
    Lizzy Sunny, Thomas Hopfgarten, Jan Adolfsson, Gunnar Steineck, Predictors for the symptomatic prostate cancer patient’s delays in seeking care, European Journal of Cancer, 2008, 44, 5, 733

    CrossRef

  39. 39
    M.R. Smith, S.B. Malkowicz, F. Chu, J. Forrest, D. Price, P. Sieber, K.G. Barnette, D. Rodriguez, M.S. Steiner, Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study, The Journal of Urology, 2008, 179, 1, 152

    CrossRef

  40. 40
    Nancy L. Keating, A. James O’Malley, Mary McNaughton-Collins, William K. Oh, Matthew R. Smith, Use of androgen deprivation therapy for metastatic prostate cancer in older men, BJU International, 2008, 101, 9
  41. 41
    Matthew R Smith, Androgen deprivation therapy for prostate cancer: new concepts and concerns, Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 3, 247

    CrossRef

  42. 42
    Jason A. Efstathiou, Kyounghwa Bae, William U. Shipley, Gerald E. Hanks, Miljenko V. Pilepich, Howard M. Sandler, Matthew R. Smith, Obesity and mortality in men with locally advanced prostate cancer, Cancer, 2007, 110, 12
  43. 43
    W. Reid Pitts, Validation of the Pitts unified theory of prostate cancer, late-onset hypogonadism and carcinoma: the role of steroid 5α-reductase and steroid aromatase, BJU International, 2007, 100, 2